8-K: Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results, Exceeding Guidance

Outset Medical's Q4 and full-year 2024 results exceeded prior guidance, with significant improvements in gross margin and recurring revenue growth.

Summary

• Outset Medical reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Net revenue for Q4 was $29.5 million and $113.7 million for the full year, both exceeding prior guidance.
• The company's gross margin in Q4 was 36.5% (37.7% non-GAAP), showing a sequential increase of 220 basis points from Q3 and an 11 percentage point increase from Q4 2023.
• Full-year gross margin was 33.9% (35.6% non-GAAP), compared to 22.2% (23.7% non-GAAP) in 2023.
• The Tablo installed base reached nearly 6,000 consoles, growing 10% in 2024.
• Recurring revenue, consisting of Tablo consumables and services, grew 13% sequentially from Q3, 17% year-over-year, and 21% to $83.9 million for the full year.
• For 2025, Outset provided revenue guidance of $115 million to $125 million and expects non-GAAP gross margin in the high-30% range.
• The company anticipates using less than $50 million of cash in 2025, compared to $103 million in 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to exceeding revenue guidance, improving gross margins, and a focus on reducing cash burn. However, the company is still operating at a loss and faces risks related to regulatory actions and macroeconomic factors.

Positives

• Revenue exceeded prior guidance for both Q4 and the full year 2024.
• Gross margins showed significant improvement both sequentially and year-over-year.
• Recurring revenue experienced substantial growth, indicating increased customer utilization and loyalty.
• Operating expenses decreased due to cost reduction efforts, streamlining operations and accelerating the path to profitability.
• Net loss per share improved compared to the previous year.
• The company anticipates using less cash in 2025 compared to 2024, indicating improved financial discipline.

Negatives

• Full year revenue declined by 13% compared to 2023.
• Product revenue decreased by 8% in Q4 and 22% for the full year compared to the prior year.
• The company still reported a net loss of $25.6 million for Q4 and $128 million for the full year.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Macroeconomic factors could impact the company, its customers, and suppliers.
• The company's ability to respond to and resolve any reports, observations, or other actions by the Food and Drug Administration or other regulators in a timely and effective manner is crucial.

Future Outlook

Outset Medical provided 2025 revenue guidance of $115 million to $125 million and expects non-GAAP gross margin in the high-30% range. The company also anticipates using less than $50 million of cash in 2025.

Management Comments

• Leslie Trigg, Chair and Chief Executive Officer, stated that the company enters 2025 with positive momentum, having delivered two solid quarters under their transforming commercial organization.
• Leslie Trigg noted that strong utilization across the Tablo installed base drove another record quarter of recurring revenue, and the strengthened balance sheet positions the company through cash flow breakeven.
• Management remains focused on supporting customers, restoring well-being to people with end-stage renal disease, and driving meaningful growth.

Industry Context

Outset Medical is focused on reducing the cost and complexity of dialysis with its Tablo Hemodialysis System, which is relevant in the context of the growing need for accessible and efficient dialysis solutions. The company's focus on recurring revenue and expanding its installed base aligns with industry trends towards subscription-based healthcare models.

Comparison to Industry Standards

• Outset Medical's gross margin improvement is a positive sign, but it still lags behind established medical device companies like Baxter and Fresenius Medical Care, which typically have gross margins in the 40-50% range.
• The growth in recurring revenue is a key indicator of the success of the Tablo system, as it demonstrates increasing utilization and customer satisfaction, similar to the business models of companies like Intuitive Surgical with their da Vinci surgical system.
• The company's focus on reducing cash burn is crucial for long-term sustainability, as many medical technology companies require significant capital investment in their early stages, similar to companies in the biotechnology sector.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and future growth prospects.
• Employees will be affected by the company's cost reduction actions and restructuring initiatives.
• Customers will benefit from the company's focus on improving the dialysis experience and simplifying operations.
• Suppliers may be impacted by the company's efforts to optimize its supply chain.

Next Steps

• The company will continue to focus on supporting customers and driving growth.
• Outset will host a conference call on February 19, 2025, to discuss the financial results.

Key Dates